FDA approves Eli Lilly’s Alzheimer’s drug Kisunla
- The Food and Drug Administration has approved Eli Lilly's Alzheimer's drug donanemab, providing more treatment choices for the disease in the U.S.
- The drug will be marketed as Kisunla and is authorized for early symptomatic Alzheimer's disease in adults.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left34Leaning Right9Center80Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 28%
C 65%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage